These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

484 related articles for article (PubMed ID: 33378214)

  • 1. How Should We Sequence the Treatments for Heart Failure and a Reduced Ejection Fraction?: A Redefinition of Evidence-Based Medicine.
    McMurray JJV; Packer M
    Circulation; 2021 Mar; 143(9):875-877. PubMed ID: 33378214
    [No Abstract]   [Full Text] [Related]  

  • 2. Obesity-Related Heart Failure With a Preserved Ejection Fraction: The Mechanistic Rationale for Combining Inhibitors of Aldosterone, Neprilysin, and Sodium-Glucose Cotransporter-2.
    Packer M; Kitzman DW
    JACC Heart Fail; 2018 Aug; 6(8):633-639. PubMed ID: 29525327
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Variation in use and dosing escalation of renin angiotensin system, mineralocorticoid receptor antagonist, angiotensin receptor neprilysin inhibitor and beta-blocker therapies in heart failure and reduced ejection fraction: Association of comorbidities.
    Albert NM; Tyson RJ; Hill CL; DeVore AD; Spertus JA; Duffy C; Butler J; Patterson JH; Hernandez AF; Williams FB; Thomas L; Fonarow GC
    Am Heart J; 2021 May; 235():82-96. PubMed ID: 33497697
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Prevention of sudden death in heart failure with reduced ejection fraction: do we still need an implantable cardioverter-defibrillator for primary prevention?
    Abdelhamid M; Rosano G; Metra M; Adamopoulos S; Böhm M; Chioncel O; Filippatos G; Jankowska EA; Lopatin Y; Lund L; Milicic D; Moura B; Ben Gal T; Ristic A; Rakisheva A; Savarese G; Mullens W; Piepoli M; Bayes-Genis A; Thum T; Anker SD; Seferovic P; Coats AJS
    Eur J Heart Fail; 2022 Sep; 24(9):1460-1466. PubMed ID: 35753058
    [TBL] [Abstract][Full Text] [Related]  

  • 5. New drugs: big changes in conservative heart failure therapy?
    Berliner D; Bauersachs J
    Eur J Cardiothorac Surg; 2019 Jun; 55(Suppl 1):i3-i10. PubMed ID: 31106335
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Efficacy of Pharmacologic and Cardiac Implantable Electronic Device Therapies in Patients With Heart Failure and Reduced Ejection Fraction: A Systematic Review and Network Meta-Analysis.
    Tseng AS; Kunze KL; Lee JZ; Amin M; Neville MR; Almader-Douglas D; Killu AM; Madhavan M; Cha YM; Asirvatham SJ; Friedman PA; Gersh BJ; Mulpuru SK
    Circ Arrhythm Electrophysiol; 2019 Jun; 12(6):e006951. PubMed ID: 31159582
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Medical therapy of heart failure with reduced ejection fraction: current evidence and new developments.
    Naegele M; Flammer AJ; Enseleit F; Ruschitzka F
    Swiss Med Wkly; 2016; 146():w14295. PubMed ID: 26968014
    [TBL] [Abstract][Full Text] [Related]  

  • 8. [A practical approach to guideline-directed pharmacological treatment for heart failure with reduced ejection fraction].
    Soltani S; Böhm M; Frey N; Eden M; Abdin A; Bauersachs J
    Dtsch Med Wochenschr; 2022 Jul; 147(14):931-938. PubMed ID: 35868319
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Full decongestion in acute heart failure therapy.
    Buttar C; Alai H; Matanes FN; Cassidy MM; Stencel J; Le Jemtel TH
    Am J Med Sci; 2024 Sep; 368(3):182-189. PubMed ID: 38880301
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Simultaneous or Rapid Sequence Initiation of Quadruple Medical Therapy for Heart Failure-Optimizing Therapy With the Need for Speed.
    Greene SJ; Butler J; Fonarow GC
    JAMA Cardiol; 2021 Jul; 6(7):743-744. PubMed ID: 33787823
    [No Abstract]   [Full Text] [Related]  

  • 11. Embracing an era of targeted combination therapy for heart failure with preserved ejection fraction.
    Shoji S; Greene SJ; Mentz RJ
    Heart Fail Rev; 2024 Nov; 29(6):1235-1238. PubMed ID: 39187605
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Patient-Centered Heart Failure Therapy.
    Samson R; Ennezat PV; Jemtel THL
    Am J Med; 2024 Jan; 137(1):23-29. PubMed ID: 37838238
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Shift of conventional paradigm of heart failure treatment: from angiotensin receptor neprilysin inhibitor to sodium-glucose co-transporter 2 inhibitors?
    Berezin AE; Berezin AA
    Future Cardiol; 2021 May; 17(3):497-506. PubMed ID: 33615880
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Pharmacologic Therapy for Heart Failure with Preserved Ejection Fraction.
    Peters AE; DeVore AD
    Cardiol Clin; 2022 Nov; 40(4):473-489. PubMed ID: 36210132
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Renin-angiotensin-aldosterone system inhibitors in heart failure.
    Shearer F; Lang CC; Struthers AD
    Clin Pharmacol Ther; 2013 Oct; 94(4):459-67. PubMed ID: 23852393
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Effectiveness of drug interventions to prevent sudden cardiac death in patients with heart failure and reduced ejection fraction: an overview of systematic reviews.
    Al-Gobari M; Al-Aqeel S; Gueyffier F; Burnand B
    BMJ Open; 2018 Jul; 8(7):e021108. PubMed ID: 30056380
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Real-World Analysis of Guideline-Based Therapy After Hospitalization for Heart Failure.
    Wirtz HS; Sheer R; Honarpour N; Casebeer AW; Simmons JD; Kurtz CE; Pasquale MK; Globe G
    J Am Heart Assoc; 2020 Aug; 9(16):e015042. PubMed ID: 32805181
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Neprilysin Inhibitors in Cardiovascular Disease.
    Kang G; Banerjee D
    Curr Cardiol Rep; 2017 Feb; 19(2):16. PubMed ID: 28185171
    [TBL] [Abstract][Full Text] [Related]  

  • 19. The renin-angiotensin-aldosterone system in heart failure for the non-specialist: the past, the present and the future.
    Orsborne C; Chaggar PS; Shaw SM; Williams SG
    Postgrad Med J; 2017 Jan; 93(1095):29-37. PubMed ID: 27671772
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Baseline Characteristics of Patients With Heart Failure and Preserved Ejection Fraction in the PARAGON-HF Trial.
    Solomon SD; Rizkala AR; Lefkowitz MP; Shi VC; Gong J; Anavekar N; Anker SD; Arango JL; Arenas JL; Atar D; Ben-Gal T; Boytsov SA; Chen CH; Chopra VK; Cleland J; Comin-Colet J; Duengen HD; Echeverría Correa LE; Filippatos G; Flammer AJ; Galinier M; Godoy A; Goncalvesova E; Janssens S; Katova T; Køber L; Lelonek M; Linssen G; Lund LH; O'Meara E; Merkely B; Milicic D; Oh BH; Perrone SV; Ranjith N; Saito Y; Saraiva JF; Shah S; Seferovic PM; Senni M; Sibulo AS; Sim D; Sweitzer NK; Taurio J; Vinereanu D; Vrtovec B; Widimský J; Yilmaz MB; Zhou J; Zweiker R; Anand IS; Ge J; Lam CSP; Maggioni AP; Martinez F; Packer M; Pfeffer MA; Pieske B; Redfield MM; Rouleau JL; Van Veldhuisen DJ; Zannad F; Zile MR; McMurray JJV
    Circ Heart Fail; 2018 Jul; 11(7):e004962. PubMed ID: 29980595
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 25.